Symptom burden after autologous stem cel
โ
Erica Campagnaro; Rima Saliba; Sergio Giralt; Linda Roden; Floralyn Mendoza; Ana
๐
Article
๐
2008
๐
John Wiley and Sons
๐
English
โ 106 KB
## Abstract ## BACKGROUND Multiple myeloma (MM) is the most common indication for highโdose chemotherapy with autologous stem cell transplantation (ASCT) in the U.S. and can be associated with substantial morbidity. Thorough assessment and understanding of symptoms and risk factors for symptom dev